GP350 AS A NOVEL VACCINE PROTEIN CARRIER

GP350 作为新型疫苗蛋白载体

• 批准号: 7562069
• 负责人: CLIFFORD M SNAPPER
• 金额: $ 10.36万
• 依托单位: HARVARD MEDICAL SCHOOL
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-05-01 至 2008-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7562069
• 关键词: Affinity; B-Lymphocytes; Biological Assay; CD4 Positive T Lymphocytes; Carrier Proteins; Computer Retrieval of Information on Scientific Projects Database; Dose; Enzyme-Linked Immunosorbent Assay; Funding; Grant; Immune; In Vitro; Institution; Macaca mulatta; Monkeys; Plasma; Purpose; Research; Research Personnel; Resources; Source; United States National Institutes of Health; aluminum sulfate; anti-IgG; cell transformation; day; follow-up; neutralizing antibody; novel vaccines; research study; young adult

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Purpose of the experiment: In our first set of experiment, we immunized young adult rhesus monkeys with varying doses of PPS14-gp350 conjugate adsorbed in alum and boosted similarly on day 28 and 42. Immune monkeys generated detectable IgG anti-PPS14 and anti-gp350 titer even with lowest dose of PPS14-gp350. As a follow up of this experiment, we would like to directly compare the ability of varying doses of alum-adsorbed unconjugated or PPS14-conjugated monomeric gp350 to: a) elicit primary, secondary, and tertiary plasma IgG anti-gp350 titers and induce affinity maturation as determined by ELISA, b) induce EBV-neutralizing antibody as determined by both an in vitro B cell transformation and ELISA neutralization assay and c) prime specific CD4+ T cells as determined by an in vitro re-stimulation assay.

该子项目是利用该技术的众多研究子项目之一 资源由 NIH/NCRR 资助的中心拨款提供。子项目及 研究者 (PI) 可能已从 NIH 的另一个来源获得主要资金， 因此可以在其他 CRISP 条目中表示。列出的机构是 对于中心来说，它不一定是研究者的机构。 实验目的：在我们的第一组实验中，我们用不同剂量的明矾吸附的 PPS14-gp350 缀合物对年轻的成年恒河猴进行免疫，并在第 28 天和第 42 天进行类似的加强。即使使用最低剂量的 PPS14-gp350，免疫猴也会产生可检测的 IgG 抗 PPS14 和抗 gp350 滴度。作为该实验的后续，我们希望直接比较不同剂量的明矾吸附的未缀合或 PPS14 缀合的单体 gp350 的能力：a) 引发初级、次级和三级血浆 IgG 抗 gp350 滴度并诱导亲和力成熟（通过 ELISA 测定），b) 诱导 EBV 中和抗体（通过体外和体外测定） B 细胞转化和 ELISA 中和测定以及 c) 通过体外再刺激测定确定的引发特异性 CD4+ T 细胞。